The shortage that made mass-market compounded GLP-1 possible is over. This page tracks what the FDA has done, what remains legal, and what that means before you pay for a compounded program.
Compounding semaglutide and tirzepatide became widespread in 2022–2024 only because both drugs were on the FDA shortage list. That window has closed.
• A valid prescription written for you specifically after an individual clinical evaluation.
• A product that is not “essentially a copy” of the commercially available branded drug.
• A documented clinical reason the FDA-approved product can’t be used.
• Compounding not done “regularly or in inordinate amounts.”
The FDA has been explicit that affordability and access do not, by themselves, count as a clinical need.